ADIM
JAZZ icon

Alpha DNA Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alpha DNA Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed -$2K – 367
2021
Q1 		$2K Hold
15
– – ﹤0.01% 567
2020
Q4 		$2K Buy
+15
New +$2.23K ﹤0.01% 464

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha DNA Investment Management's JAZZ Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2021, closing a stake of 15 shares — an estimated $2K sold.

Alpha DNA Investment Management first reported a position in JAZZ in Q4 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2021. 505 funds tracked by Wall St. Rank hold JAZZ as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Jazz Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 15 Jazz Pharmaceuticals shares in Q2 2021, an estimated $2K.
  • Alpha DNA Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Jazz Pharmaceuticals position peaked at $2K in Q1 2021.
  • 505 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.